

Supplementary material

Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice cross-titration schedules in a *post hoc* analysis of a randomized, double-blind, maintenance treatment study

Christoph U Correll,¹ Lily Shi,² Catherine Weiss,² Mary Hobart,² Anna Eramo,³ Ruth A Duffy,² Emmanuelle Weiller,⁴ Ross A Baker²

¹Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York, USA; and Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.

²Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.

³Lundbeck LLC, Deerfield, IL, USA.

⁴H. Lundbeck A/S, Valby, Copenhagen, Denmark.

Supplementary Table 1. Treatment-emergent adverse events (TEAEs) with incidence $\geq 2.0\%$ in any conversion group, for patients who converted to brexpiprazole and completed 8 weeks, in the 8 weeks from the start of the conversion phase (the first dose of brexpiprazole)

n (%)	Total (N=404)	Converted and completed 8 weeks				Total completed 8 weeks (n=292)	Total discontinued in <8 weeks (n=112)
		1–7 days (n=7)	8–14 days (n=19)	15–21 days (n=32)	22–33 days (n=234)		
Insomnia	45 (11.1)	2 (28.6)	3 (15.8)	7 (21.9)	27 (11.5)	39 (13.4)	6 (5.4)
Headache	29 (7.2)	1 (14.3)	3 (15.8)	2 (6.3)	14 (6.0)	20 (6.8)	9 (8.0)
Agitation	25 (6.2)	1 (14.3)	1 (5.3)	2 (6.3)	12 (5.1)	16 (5.5)	9 (8.0)
Akathisia	21 (5.2)	0 (0.0)	1 (5.3)	2 (6.3)	13 (5.6)	16 (5.5)	5 (4.5)
Nasopharyngitis	18 (4.5)	0 (0.0)	3 (15.8)	1 (3.1)	10 (4.3)	14 (4.8)	4 (3.6)
Nausea	13 (3.2)	0 (0.0)	1 (5.3)	1 (3.1)	7 (3.0)	9 (3.1)	4 (3.6)
Dizziness	10 (2.5)	0 (0.0)	0 (0.0)	0 (0.0)	8 (3.4)	8 (2.7)	2 (1.8)
Tremor	10 (2.5)	0 (0.0)	0 (0.0)	2 (6.3)	4 (1.7)	6 (2.1)	4 (3.6)
Diarrhea	9 (2.2)	1 (14.3)	1 (5.3)	0 (0.0)	5 (2.1)	7 (2.4)	2 (1.8)
Schizophrenia	9 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)	1 (0.3)	8 (7.1)
Extrapyramidal disorder	8 (2.0)	0 (0.0)	1 (5.3)	2 (6.3)	5 (2.1)	8 (2.7)	0 (0.0)
Constipation	8 (2.0)	0 (0.0)	3 (15.8)	2 (6.3)	1 (0.4)	6 (2.1)	2 (1.8)
Vomiting	7 (1.7)	1 (14.3)	1 (5.3)	1 (3.1)	3 (1.3)	6 (2.1)	1 (0.9)
Abdominal discomfort	6 (1.5)	1 (14.3)	1 (5.3)	1 (3.1)	3 (1.3)	6 (2.1)	0 (0.0)
Upper respiratory tract infection	6 (1.5)	1 (14.3)	0 (0.0)	1 (3.1)	4 (1.7)	6 (2.1)	0 (0.0)
Increased appetite	5 (1.2)	1 (14.3)	0 (0.0)	0 (0.0)	4 (1.7)	5 (1.7)	0 (0.0)
Dyspepsia	5 (1.2)	0 (0.0)	1 (5.3)	0 (0.0)	3 (1.3)	4 (1.4)	1 (0.9)
Somnolence	5 (1.2)	0 (0.0)	1 (5.3)	0 (0.0)	4 (1.7)	5 (1.7)	0 (0.0)

Toothache	5 (1.2)	0 (0.0)	0 (0.0)	1 (3.1)	3 (1.3)	4 (1.4)	1 (0.9)
Weight increased	4 (1.0)	1 (14.3)	1 (5.3)	0 (0.0)	2 (0.9)	4 (1.4)	0 (0.0)
Arthralgia	4 (1.0)	1 (14.3)	0 (0.0)	0 (0.0)	2 (0.9)	3 (1.0)	1 (0.9)
Back pain	4 (1.0)	0 (0.0)	2 (10.5)	1 (3.1)	0 (0.0)	3 (1.0)	1 (0.9)
Sedation	4 (1.0)	0 (0.0)	1 (5.3)	1 (3.1)	1 (0.4)	3 (1.0)	1 (0.9)
Anxiety	4 (1.0)	0 (0.0)	1 (5.3)	1 (3.1)	2 (0.9)	4 (1.4)	0 (0.0)
Fatigue	3 (0.7)	0 (0.0)	2 (10.5)	0 (0.0)	1 (0.4)	3 (1.0)	0 (0.0)
Neck pain	3 (0.7)	0 (0.0)	1 (5.3)	0 (0.0)	2 (0.9)	3 (1.0)	0 (0.0)
Vision blurred	3 (0.7)	0 (0.0)	1 (5.3)	0 (0.0)	1 (0.4)	2 (0.7)	1 (0.9)
Cough	3 (0.7)	0 (0.0)	1 (5.3)	0 (0.0)	2 (0.9)	3 (1.0)	0 (0.0)
Oropharyngeal pain	3 (0.7)	0 (0.0)	1 (5.3)	0 (0.0)	1 (0.4)	2 (0.7)	1 (0.9)
Rhinitis	3 (0.7)	0 (0.0)	0 (0.0)	1 (3.1)	2 (0.9)	3 (1.0)	0 (0.0)
Blood creatine phosphokinase increased	3 (0.7)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	2 (1.8)
Muscle spasms	2 (0.5)	1 (14.3)	0 (0.0)	1 (3.1)	0 (0.0)	2 (0.7)	0 (0.0)
Blood pressure increased	2 (0.5)	1 (14.3)	0 (0.0)	0 (0.0)	1 (0.4)	2 (0.7)	0 (0.0)
Musculoskeletal chest pain	2 (0.5)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.9)
Type 2 diabetes mellitus	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	1 (0.4)	2 (0.7)	0 (0.0)
Myalgia	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.9)
Dyskinesia	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.9)
Lethargy	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.9)
Atrioventricular block first degree	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	1 (0.4)	2 (0.7)	0 (0.0)
Urinary tract infection	2 (0.5)	0 (0.0)	1 (5.3)	0 (0.0)	1 (0.4)	2 (0.7)	0 (0.0)

Bronchitis	2 (0.5)	0 (0.0)	0 (0.0)	1 (3.1)	1 (0.4)	2 (0.7)	0 (0.0)
Pharyngitis	2 (0.5)	0 (0.0)	0 (0.0)	1 (3.1)	1 (0.4)	2 (0.7)	0 (0.0)
Hypoesthesia	1 (0.2)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Abdominal pain	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Gastroenteritis	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Tinea pedis	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Muscle rigidity	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Drooling	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Dysarthria	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Paresthesia	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Calculus urinary	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Asthma	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Hidradenitis	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Rash generalized	1 (0.2)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)
Conjunctivitis	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)
Pneumonia	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)
Muscle fatigue	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)
Musculoskeletal stiffness	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)
Epistaxis	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)
Nasal congestion	1 (0.2)	0 (0.0)	0 (0.0)	1 (3.1)	0 (0.0)	1 (0.3)	0 (0.0)

Data for patients who received at least one dose of brexpiprazole in the conversion phase.